Pharmaceutical collaborates with world-class pharmaceutical
and biotechnology companies to identify cutting-edge
therapeutics for China's largest pharmaceutical segments. Once
target drugs with the highest probability of success are
selected, we work with our partners to bring them to market.
Our competencies span the entire range of drug registration,
marketing and distribution, and can be tailored to fit each
partner's unique business needs. In general, however, our
partnerships fall into two main categories: licensing and
strategic. In the case of licensing arrangements –
optimal for smaller companies or research institutions
who require a full battery of services – PUMC
will license the drug and handle all aspects of Registration,
Insurance Reimbursement, Manufacturing
and Marketing in China, while paying
out royalties to the partner on sales of the drug. In
the case of strategic alliances, PUMC manages all stages
of registration and insurance reimbursement for a retainer
and success fee.
We currently market several gastroenterology and anesthesiology
products in China, and are actively working towards launching
drugs for the following indications: oncology, renal failure,
neurology, and ICU/CCU.
Registration. China’s bureaucratic
tangles are notorious worldwide, and are especially
complex with regards to matters as sensitive and critical
as drug registration. Currently, fewer than 30% of the
registration applications for imported drugs are ever
approved, and of those fewer than 30% are ever approved
for renewal after the initial three years.
relationships with the China Academy of Medicine
(CAM), Peking Union Medical College (PUMC), State
Drug Administration (SDA) and key VIP physicians
and researchers all ensure the most expeditious
process possible – from application, through
review, through clinical trials, to approval.
Even drugs that are ultimately approved do not sell
unless they qualify for insurance reimbursement.
widespread network of specialists work with the
appropriate agencies to secure these necessary approvals
All production plants without GMP certification will
be shut down after the 2004 moratorium. As of April
2002, 56% of the country’s pharmaceutical plants
had yet to pass inspection.
two state-of-the-art, GMP-certified manufacturing
facilities ensure that partners’ products
are manufactured to their exacting standards.
Marketing. All ethical drugs are dispensed
from hospital pharmacies, and therefore require an extensive
network of connections into the nation’s top hospitals
for effective sales.
M.D.- and Pharm.D.-dominated sales force sells into
their connections with over 500 major teaching hospitals
by a) organizing high-profile symposia to introduce
the product to a broad audience, b) organizing quarterly
seminars at teaching hospitals throughout China,
c) performing daily hospital visits to promote to
key decision makers and d) publishing papers and
selective advertisements in the medical press.